SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (date of earliest event reported): December 7, 2006.
BioTime,
Inc.
(Exact
name of registrant as specified in its charter)
|
California
|
1-12830
|
94-3127919
|
|
(State
or other jurisdiction of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification
No.)
|
|
|
||
6121
Hollis Street
Emeryville,
California 94608
(Address
of principal executive offices)
(510)
350-2940
(Registrant's
telephone number, including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[
]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[
]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
[
]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Statements
made in this Report that are not historical facts may constitute forward-looking
statements that are subject to risks and uncertainties that could cause actual
results to differ materially from those discussed. Such risks and uncertainties
include but are not limited to those discussed in this report and in BioTime's
Annual Report on Form 10-K filed with the Securities and Exchange Commission.
Words such as “expects,” “may,” “will,” “anticipates,” “intends,” “plans,”
“believes,” “seeks,” “estimates,” and similar expressions identify
forward-looking statements.
Section
7 Regulation
FD
Item
7.01 Regulation FD Disclosure
The
press
release filed as Exhibit 99.1 is incorporated by reference.
Section
9-Financial Statements and Exhibits
Item
9.01 Financial Statements and Exhibits.
Exhibit
Number Description
99.1 Press
release dated December 7, 2006
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
BIOTIME,
INC.
|
Date:
December 7, 2006
|
By:
/s/Judith
Segall
|
|
|
Vice
President - Operations
|
||
|
Member,
Office of the President
|
Exhibit
Number Description
99.1 Press
release dated December 7, 2006
Exhibit
99.1
BioTime,
Inc. 6121
Hollis Street
Emeryville,
CA 94608
Tel:
510-350-2940
Fax:
510-350-2948
www.biotimeinc.com
For
Further Information:
Judith
Segall (510) 350-2940
FOR
IMMEDIATE RELEASE
December
7, 2006
BIOTIME
ANNOUNCES A PHASE II CLINICAL TRIAL
OF
HEXTEND®
IN JAPAN
EMERYVILLE,
CA, December 7, 2006 - BioTime,
Inc. (OTCBB: BTIM) announced today that a Phase II clinical trial for Hextend®
is being conducted in Japan by Summit Pharmaceuticals International Corporation
under their license agreement with BioTime. Summit is co-developing Hextend
for
the Japanese market with Maruishi Pharmaceutical Co., Ltd. and both
Maruishi and Summit have the right to co-market Hextend if regulatory approval
is obtained.
Summit
expects Phase III clinical studies to commence in 2008.
Hextend
has been formulated to restore and maintain plasma volume longer than the plasma
volume expanders currently marketed in Japan. Summit estimates that there are
on
average at least 1 million surgery cases per year in Japan that involve the
use
of plasma volume expanders.
Hextend
is a physiologically balanced blood plasma volume expander, for the treatment
of
hypovolemia. Hextend is being distributed in the United States and Canada by
Hospira, Inc. and in South Korea by CJ Corp. under exclusive licenses from
BioTime. Hospira also has the right to obtain regulatory approval and market
Hextend in Latin America and Australia. Summit has a license to develop Hextend
in Japan, the People’s Republic of China, and Taiwan.
BioTime,
headquartered in Emeryville, California develops blood plasma volume expanders,
blood replacement solutions for hypothermic (low temperature) surgery, organ
preservation solutions and technology for use in surgery, emergency trauma
treatment, and other applications. Information about BioTime can be found on
the
web at www.biotimeinc.com.
The
matters discussed in this press release include forward-looking statements
which
are subject to various risks, uncertainties and other factors that could cause
actual results to differ materially from the results anticipated. Such risks
and
uncertainties include but are not limited to the results of clinical trials
of
Hextend®,
the
ability of Summit and Maruishi to obtain regulatory approval to market
Hextend®
in
Japan; competition from products manufactured and sold or being developed by
other companies; the price of and demand for Hextend®;
and the
availability of reimbursement for the cost of Hextend®
and
related treatment from government health administration authorities, private
health coverage insurers and other organizations. These and other risk factors
are discussed in BioTime’s Annual Report on Form 10-K filed with the Securities
and Exchange Commission.